General
Preferred name
Gadoteric acid
Synonyms
GADOTERATE MEGLUMINE ()
P&D ID
PD009038
CAS
83678-67-5
Tags
drug
contains metal
available
Drug Status
approved
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Gadoterate affects proton relaxation times and consequently the MR signal, and the contrast obtained is characterized by the relaxivity of the gadoterate molecule. The relaxivity values for gadoterate are similar across the spectrum of magnetic field strengths used in clinical MRI (0.2 - 1.5 T).; Gadoterate does not cross the intact blood-brain barrier and, therefore, does not enhance normal brain or lesions that have a normal blood-brain barrier, e.g. cysts, mature post-operative scars. However, disruption of the blood-brain barrier or abnormal vascularity allows distribution of gadoterate in lesions such as neoplasms, abscesses, and infarcts.
Compound Sets
3
DrugBank
DB09132
DrugBank Approved Drugs
DB09132
DrugMatrix
External IDs
22
Properties
(calculated by RDKit )
Molecular Weight
559.09
Hydrogen Bond Acceptors
11
Hydrogen Bond Donors
1
Rotatable Bonds
8
Ring Count
1
Aromatic Ring Count
0
cLogP
-6.46
TPSA
170.65
Fraction CSP3
0.75
Chiral centers
0.0
Largest ring
12.0
QED
0.3
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Source data